Fermin Paul Pacheco-Moises

Dr. Fermin Paul Pacheco-Moises


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Archives of Medical Research
Verified
Journal Article
Closed access
GOGenaro Gabriel Ortiz
Genaro Gabriel Ortiz
FPFermin Paul Pacheco-Moises
Fermin Paul Pacheco-Moises
MMMiguel Angel Macias
Miguel Angel Macias
LFLuis Javier Flores-Alvarado
Luis Javier Flores-Alvarado
MMMario A. Mireles-Ramírez
Mario A. Mireles-Ramírez
MAMoisés Alejandro Alatorre-Jiménez
Moisés Alejandro Alatorre-Jiménez

24 September 2013 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
GOGenaro Gabriel Ortiz
Genaro Gabriel Ortiz
FPFermin Paul Pacheco-Moises
Fermin Paul Pacheco-Moises
OQOscar Kurt Bitzer Quintero
Oscar Kurt Bitzer Quintero
ARAna C. Ramírez-Anguiano
Ana C. Ramírez-Anguiano
LFLuis J. Flores-Alvarado
Luis J. Flores-Alvarado
ETErandis D. Torres-Sánchez
Erandis D. Torres-Sánchez
Multiple sclerosis (MS) exhibits many of the hallmarks of an inflammatory autoimmune disorder including breakdown of the blood-brain barrier (BBB), the recruitment of lymphocytes, microglia, and macrophages to lesion sites, the presence of multiple lesions, generally being more pronounced in the brain stem and spinal cord, the predominantly perivascular location of lesions, the temporal maturation of lesions from inflammation through demyelination, to gliosis and partial remyelination, and the presence of immunoglobulin in the central nervous system and cerebrospinal fluid. Lymphocytes activated in the periphery infiltrate the central nervous system to trigger a local immune response that ultimately damages myelin and axons. Pro-inflammatory cytokines amplify the inflammatory cascade by compromising the BBB, recruiting immune cells from the periphery, and activating resident microglia. inflammation-associated oxidative burst in activated microglia and macrophages plays an important role in the demyelination and free radical-mediated tissue injury in the pathogenesis of MS. The inflammatory environment in demyelinating lesions leads to the generation of oxygen- and nitrogen-free radicals as well as proinflammatory cytokines which contribute to the development and progression of the disease. Inflammation can lead to oxidative stress and vice versa. Thus, oxidative stress and inflammation are involved in a self-perpetuating cycle.

24 October 2017 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
SSSonia Sifuentes-Franco
Sonia Sifuentes-Franco
FPFermin Paul Pacheco-Moises
Fermin Paul Pacheco-Moises
ARAdolfo Daniel Rodríguez-Carrizalez
Adolfo Daniel Rodríguez-Carrizalez
ADAlejandra Guillrmina Miranda Díaz
Alejandra Guillrmina Miranda Díaz
Diabetic polyneuropathy (DPN) is the most frequent and prevalent chronic complication of diabetes mellitus (DM). The state of persistent hyperglycemia leads to an increase in the production of cytosolic and mitochondrial reactive oxygen species (ROS) and favors deregulation of the antioxidant defenses that are capable of activating diverse metabolic pathways which trigger the presence of nitro-oxidative stress (NOS) and endoplasmic reticulum stress. Hyperglycemia provokes the appearance of micro- and macrovascular complications and favors oxidative damage to the macromolecules (lipids, carbohydrates, and proteins) with an increase in products that damage the DNA. Hyperglycemia produces mitochondrial dysfunction with deregulation between mitochondrial fission/fusion and regulatory factors. Mitochondrial fission appears early in diabetic neuropathy with the ability to facilitate mitochondrial fragmentation. Autophagy is a catabolic process induced by oxidative stress that involves the formation of vesicles by the lysosomes. Autophagy protects cells from diverse stress factors and routine deterioration. Clarification of the mechanisms involved in the appearance of complications in DM will facilitate the selection of specific therapeutic options based on the mechanisms involved in the metabolic pathways affected. Nowadays, the antioxidant agents consumed exogenously form an adjuvant therapeutic alternative in chronic degenerative metabolic diseases, such as DM.

18 June 2013 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
VRV. Ramirez-Ramirez
V. Ramirez-Ramirez
MMMiguel Angel Macias
Miguel Angel Macias
GOGenaro Gabriel Ortiz
Genaro Gabriel Ortiz
FPFermin Paul Pacheco-Moises
Fermin Paul Pacheco-Moises
ETE. D. Torres-Sanchez
E. D. Torres-Sanchez
ARA. J. Celis de la Rosa
A. J. Celis de la Rosa
Multiple sclerosis (MS) is a chronic inflammatory disease, which leads to focal plaques of demyelination and tissue injury in the central nervous system. Oxidative stress is also thought to promote tissue damage in multiple sclerosis. Current research findings suggest that omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapenta-enoic acid (EPA) and docosahexaenoic acid (DHA) contained in fish oil may have anti-inflammatory, antioxidant, and neuroprotective effects. The aim of the present work was to evaluate the efficacy of fish oil supplementation on serum proinflammatory cytokine levels, oxidative stress markers, and disease progression in MS. 50 patients with relapsing-remitting MS were enrolled. The experimental group received orally 4 g/day of fish oil for 12 months. The primary outcome was serum TNFαlevels; secondary outcomes were IL-1β1b, IL-6, nitric oxide catabolites, lipoperoxides, progression on the expanded disability status scale (EDSS), and annualized relapses rate (ARR). Fish oil treatment decreased the serum levels of TNFα, IL-1β, IL-6, and nitric oxide metabolites compared with placebo group (P≤0.001). There was no significant difference in serum lipoperoxide levels during the study. No differences in EDSS and ARR were found.Conclusion.Fish oil supplementation is highly effective in reducing the levels of cytokines and nitric oxide catabolites in patients with relapsing-remitting MS.

1 August 2018 in Archives of Medical Research
Verified
Journal Article
Closed access
ALAngélica Lizeth Sánchez López
Angélica Lizeth Sánchez López
GOGenaro Gabriel Ortiz
Genaro Gabriel Ortiz
FPFermin Paul Pacheco-Moises
Fermin Paul Pacheco-Moises
MMMario A. Mireles-Ramírez
Mario A. Mireles-Ramírez
OBOscar K. Bitzer-Quintero
Oscar K. Bitzer-Quintero
IVIrma E. Velázquez-Brizuela
Irma E. Velázquez-Brizuela

1 February 2006 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
GOGenaro Gabriel Ortiz
Genaro Gabriel Ortiz
OQOscar Kurt Bitzer Quintero
Oscar Kurt Bitzer Quintero
CZC. Beas Zárate
C. Beas Zárate
SRS. Rodríguez-Reynoso
S. Rodríguez-Reynoso
FLF. Larios-Arceo
F. Larios-Arceo
SRS.A. Rosales-Corral
S.A. Rosales-Corral